Log in
NASDAQ:ARIA

589378 Stock Forecast, Price & News

Notice: This company has been marked as potentially delisted and may not be actively trading.
$23.99
0.00 (0.00 %)
(As of 02/17/2017)
Add
Today's Range
$23.99
Now: $23.99
$23.99
50-Day Range N/A
52-Week Range
$4.67
Now: $23.99
$23.99
VolumeN/A
Average Volume15.70 million shs
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
BetaN/A
ARIAD Pharmaceuticals, Inc. (ARIAD) is an oncology company. The Company is focused on transforming the lives of cancer patients with medicines. The Company's product pipeline includes Iclusig (ponatinib), brigatinib, AP32788 and ridaforolimus. The Company's Iclusig is a tyrosine kinase inhibitor (TKI) that is approved in the United States, the European Union, Australia, Switzerland, Israel and Canada for the treatment of adult patients with chronic myeloid leukemia (CML), and Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL). Its Brigatinib is an investigational inhibitor of anaplastic lymphoma kinase (ALK). Its AP32788 is a TKI, which is designed as a targeted therapy for patients with non-small cell lung cancer (NSCLC) with specific mutations in two kinases, epidermal growth factor receptor (EGFR), or human epidermal growth factor receptor 2 (HER2). Its Ridaforolimus is an investigational inhibitor of the mammalian target of rapamycin (mTOR).
Read More
589378 logo

Beat the Market (BTM) Rank

Analyst Opinion: 0.0Community Rank: 2.8Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

0.76 out of 5 stars

Industry, Sector and Symbol

Industry N/A
Sub-IndustryBiotechnology
SectorN/A
Current SymbolNASDAQ:ARIA
CUSIP04033A10
Phone+1-617-4940400
EmployeesN/A

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A

Profitability

Miscellaneous

Next Earnings DateN/A
OptionableOptionable

Receive ARIA News and Ratings via Email

Sign-up to receive the latest news and ratings for ARIA and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











589378 (NASDAQ:ARIA) Frequently Asked Questions

How were 589378's earnings last quarter?

589378 (NASDAQ:ARIA) posted its earnings results on Thursday, July, 28th. The pharmaceutical company reported $0.59 earnings per share (EPS) for the quarter, topping the Thomson Reuters' consensus estimate of ($0.11) by $0.70. The pharmaceutical company earned $65.30 million during the quarter, compared to the consensus estimate of $60.64 million. The firm's revenue for the quarter was up 133.0% compared to the same quarter last year. During the same period in the previous year, the business earned ($0.28) earnings per share.
View 589378's earnings history
.

Who are some of 589378's key competitors?

What other stocks do shareholders of 589378 own?

Based on aggregate information from My MarketBeat watchlists, some companies that other 589378 investors own include Synergy Pharmaceuticals (SGYP), Twitter (TWTR), Exelixis (EXEL), Gilead Sciences (GILD), ACADIA Pharmaceuticals (ACAD), Achillion Pharmaceuticals (ACHN), Array Technologies (ARRY), Alphabet (GOOG), Netflix (NFLX) and Ford Motor (F).

What is 589378's stock symbol?

589378 trades on the NASDAQ under the ticker symbol "ARIA."

What is 589378's stock price today?

One share of ARIA stock can currently be purchased for approximately $23.99.

What is 589378's official website?

The official website for 589378 is www.ariad.com.

How can I contact 589378?

589378's mailing address is 125 Binney St, CAMBRIDGE, MA 02142-1123, United States. The pharmaceutical company can be reached via phone at +1-617-4940400.

This page was last updated on 10/27/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.